NCT05061537 · OUTCOME

Part 2: Percentage of Participants With Positive Anti-drug Antibodies Against PF-07263689 and Sasanlimab

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors · Source last updated 2024-04-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: From first dose of study treatment until 60 days after last dose of study treatment (up to 2 years)

Analysis population: Data was not collected as no participants were enrolled in Part 2 of the study due to study termination.

Groups in this outcome

Participants were planned to receive PF-07263689 in combination with sasanlimab at the preliminary combination recommended Phase 2 dose from Part 1B.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Part 2: PF-07263689 + Sasanlimab	0

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denoms

groups

population Description

Data was not collected as no participants were enrolled in Part 2 of the study due to study termination.

reporting Status

POSTED

time Frame

From first dose of study treatment until 60 days after last dose of study treatment (up to 2 years)

title

Part 2: Percentage of Participants With Positive Anti-drug Antibodies Against PF-07263689 and Sasanlimab

type

SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice